FDA OKs First Oral Agent for Eosinophilic Esophagitis FDA OKs First Oral Agent for Eosinophilic Esophagitis

Budesonide oral suspension is indicated for 12 weeks of treatment of EoE in adults and children as young as 11 years.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Gastroenterology Source Type: news